Ioxaglate Versus Iodixanol for the Prevention of Contrast-induced Nephropathy in High-risk Patients (IDPC Trial)
IDPC
1 other identifier
observational
2,262
0 countries
N/A
Brief Summary
Contrast media-induced nephropathy following diagnostic and therapeutic cardiac catheterization.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2016
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 1, 2016
CompletedStudy Start
First participant enrolled
December 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2016
CompletedFirst Posted
Study publicly available on registry
December 13, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2020
CompletedDecember 14, 2016
December 1, 2016
Same day
December 1, 2016
December 12, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Contrast-induced nephropathy incidence
Between 48 and 96 hours after diagnostic and therapeutic cardiac catheterization
Secondary Outcomes (2)
Composite of death or need for dialysis in 48 to 96 hours and at 30 days after diagnostic and therapeutic cardiac catheterization
30 days
The individual components of the combined outcome (total mortality or dialysis indication)
30 days
Study Arms (2)
Iodixanol
Iodixanol contrast media
Ioxaglate
Ioxaglate contrast media
Interventions
Eligibility Criteria
Patients undergoing coronary angiography or percutaneous interventions will be eligible for the trial if they have at least 1 risk factor for contrast-induced acute kidney injury
You may qualify if:
- At least one of the following criteria
- Aged more than 70 years-old
- Chronic renal failure
- Diabetes mellitus
- Congestive heart failure - left ventricular ejection fraction \< 0.50
- Shock or intra-aortic ballon pump use
- Urgency or emergency procedures
You may not qualify if:
- Patients in dialysis
- Allergy to iodine
- Patient refusal to informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Freitas RAP, Tanajura LF, Mehran R, Chamie D, Chaves A, Centemero M, Braga S, Costa R, Cao D, Sousa A, Feres F, Costa JR Jr. Ioxaglate Versus IoDixanol for the Prevention of Contrast-Induced Nephropathy: The IDPC Trial. J Invasive Cardiol. 2023 Jun;35(6):E281-E290. doi: 10.25270/jic/21.00249. Epub 2023 May 16.
PMID: 37220640DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
December 1, 2016
First Posted
December 13, 2016
Study Start
December 1, 2016
Primary Completion
December 1, 2016
Study Completion
November 1, 2020
Last Updated
December 14, 2016
Record last verified: 2016-12